Sep 04, 2019
Soliton Announces IRB Approval for Keloid Trial
Aug 26, 2019
Soliton Engages argodesign in Preparation of Commercial Launch of its RAP Device
Aug 20, 2019
Soliton Announces Positive Results Demonstrated from Longer RAP Treatment
Aug 16, 2019
Dr. Michael Kaminer Presented Soliton RAP for Cellulite at Key Dermatology Conference
Aug 14, 2019
Soliton Treats First Patients in Pivotal Cellulite Trial
Aug 06, 2019
Soliton Completes Site Enrollment and Conducts Initial Site Training to Start Pivotal Cellulite Trial
Aug 01, 2019
Soliton Announces Global Nasdaq Partner Sanmina Delivers RAP Device to More Effectively Target Cellulite Reduction for Pivotal Trial
Jul 29, 2019
Soliton Announces IRB Approval
Jul 23, 2019
Soliton's FDA Cleared Device is Granted Key Patent
Jul 16, 2019
Soliton Announces Submission for IRB Approval of Pivotal Cellulite Trial Protocol
Jul 15, 2019
Soliton Announces Positive 26-week Cellulite Clinical Trial Results Demonstrate Long-Term Improvement
Jul 10, 2019
Soliton Expands Clinical Trial Sites to include SkinCare Physicians
Jul 08, 2019
Soliton to Announce Cellulite Trial Data for 26-Week Period on July 15, 2019
Jul 02, 2019
Soliton Announces Filing of Form S-1 Registering the Shares Issued in Private Placement at $14.00 per Unit
Jun 28, 2019
Soliton's Inclusion in the Russell 2000 and 3000 will be Effective After the Close of the Market Today
Jun 25, 2019
Soliton Engages CRO to begin Pivotal Cellulite Trial
May 28, 2019
Soliton Receives FDA 510(k) Clearance of its Acoustic Shockwave RAP Device
May 17, 2019
Soliton Provides FDA Update and Addresses Recent Anonymous Article
May 16, 2019
Soliton's RAP Device Able to Penetrate Vacuole Shielding; Targets $4 Billion Potential Tattoo Removal Market
May 14, 2019
Soliton Receives Approval for New Patent for its Acoustic Shockwave Technology